In vivo and in vitro sensitivity of Blastic Plasmacytoid Dendritic Cell Neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

**Treatment**

- Biological agent SL-401: recombinant IL-3 fused to diptheria toxin
- Other chemotherapeutic drugs

**Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)**

**in vitro model**
- high IL-3 receptor expression
- Cell lines or primary cells from patients

**in vivo model**
- NSG mice inoculated with BPDCN IL-3R+++ cell line

**Response**
- Positive
- Neutral
- Negative

Angelot-Delettre et al., Haematologica, 2015